ID   P7731
DR   cancercelllines; CVCL_RY01
DR   Cosmic; 2814455
DR   EGA; EGAS00001002840
DR   GEO; GSM2769404
DR   GEO; GSM2769405
DR   GEO; GSM2769406
DR   GEO; GSM2785715
DR   Wikidata; Q54937316
RX   PubMed=28889351;
RX   PubMed=29468485;
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Doubling time: ~24 hours (Direct_author_submission).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Unspecified (PubMed=28889351; PubMed=29468485).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys229Ter (c.687T>A); Zygosity=Unspecified (PubMed=28889351; PubMed=29468485).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Miscellaneous: Doubling time and age of donor from personal communication of Chenevix-Trench G.
CC   Miscellaneous: Conflicts in the STR profile of markers TH01 and vWA between PubMed=28889351 and PubMed=29468485 are clerical errors and are thus not recorded in the relevant section (personal communication of Chenevix-Trench G.).
CC   Derived from site: Metastatic; Bone; UBERON=UBERON_0002481.
ST   Source(s): PubMed=28889351; PubMed=29468485
ST   Amelogenin: X
ST   CSF1PO: 13,14
ST   D13S317: 11,12
ST   D16S539: 11
ST   D21S11: 31,31.2
ST   D5S818: 9
ST   D7S820: 8,11
ST   TH01: 8,9.3
ST   TPOX: 8,9
ST   vWA: 14,17
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   40Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 05-10-23; Version: 10
RX   PubMed=28889351; DOI=10.1007/s10549-017-4496-x;
RA   Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L.,
RA   Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E.,
RA   Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J.,
RA   Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E.,
RA   Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F.,
RA   Lakhani S.R.;
RT   "Multidimensional phenotyping of breast cancer cell lines to guide
RT   preclinical research.";
RL   Breast Cancer Res. Treat. 167:289-301(2018).
RX   PubMed=29468485; DOI=10.1007/s10549-018-4719-9;
RA   Johnson J., Bessette D.C., Saunus J.M., Smart C.E., Song S.,
RA   Johnston R.L., Cocciardi S., Rozali E.N., Johnstone C.N., Vargas A.C.,
RA   Kazakoff S.H., Khanna K.K., Lakhani S.R., Chenevix-Trench G.,
RA   Simpson P.T., Nones K., Waddell N., Al-Ejeh F.;
RT   "Characterization of a novel breast cancer cell line derived from a
RT   metastatic bone lesion of a breast cancer patient.";
RL   Breast Cancer Res. Treat. 170:179-188(2018).